Member Info for Merchantbanker

Imagine changing your whole opinion of a company because directors sold a small portion of their options likely for tax reasons and on the advice of their advisors, many of which they are over 500% up on and have held for 5-10 years. And still have millions of combined interest. Directors fully deserve the opportunity to put some money in the bank in these circumstances.

Well done JAdam you sold a company at 92p that will be worth multiples of that in months and years to come.

Whether you believe in candlestick patterns or not you have to apply them correctly, rather than just trying to find something to suit your narrative.

Yes it's dropped 10p from a share price that was already significantly undervalued. Most people couldn't give a toss about 10p swing as many are here for the significant returns this will without doubt generate.

I have no concerns about tests or orders. They are already producing.

Skating on thin ice.... really... as by all accounts they are on the verge of substantial revenues for the foreseeable and longer term.

I see a lot of frustration around. Some understandable. We deserve more info, but we are here. 2m a week capacity. That capacity is the money maker. We have already had more news than is priced in today. They have a portfolio of tests to fill that capacity. And it will be used to the max. Every single product in the portfolio has its appeal, and they could use the capacity with a smaller portfolio than they have.

LFT and diagnostics is and will be in a whole new league as an industry. Still people are suffering form short termism. Diagnostics and LFT manufacturing will thrive for years to come. Technology, development, science and research will only improve.

ODX will be a low risk money making machine, and they are about to up the ante.,

3 black crows.... pmsl!

Someone trying to justify selling out or aim for buying back in lower...

For a start the 3 red candles are still withing the previous swing low, and ODX is still in an uptrend and the red candles take ODX in to a major support area. This has been traded sidewards since 8th Feb, and there is a very bullish accumulation evident in the chart.

This will help explain why JAdam is talking rubbish for anyone who can't see that.

As for the "sells". We can't be sure what they are being all the smoke and mirrors, but as someone who has w2atched this closer than ever today, it's clear to me stock is in demand by MMs not being offloaded.

https://www.tradingwithrayner.com/three-black-crows-candlestick/

If you read the full document, the sentence that immediately proceeds the one quoted is as follows:

“This second call is for partners to provide more materials for evaluation but specifically for Nucleocapsid protein detection.”

I think that couldn’t be any clearer.

https://www.bioindustry.org/news-listing/new-antibody-reagents-for-covid-rapid-nucleocapsid-antigen-lateral-flow-tests.html

It’s not informative it is factually incorrect. If that makes me a prick for pointing that out so be it!

Aptamers are generic nobody owns the IP to generic Aptamers. Aptamer group own the IP to Optimers which are modified Aptamers. Aptamer ownership of Optimers is no different to AVCT ownership of Affimers.

What CB fails to point out is the word written in bold font.... nucleocapsid. So it appears they are targeting the n protein not then S. So unless AVCT are also developing Affimers to the N protein, the information that CB refers to argues the case against Avacta as much as it does Aptamer.

Now Avacta have gone to Mologic they have a real shot at getting a test to market. So you don’t need to make things up to discredit other tests or champion the importance of AVCT. Just get the facts right. Seems to me CB is concerned about the competition from Aptamer and looking for a reason to discredit them.

One of the things people forget when they look at Covid revenues and how long they may last, is that this is not the end of the story.

ODX will build a big cash position which has the opportunity to be far in excess of today’s MCAP.

Dividends, share buy backs will be very possible options. So is further investment in new products and the longer term diagnostics play. Diagnostics importance and profile will only increase through and beyond Covid.

So whichever way you look at it, there is substantial short and long term value for investors and whatever they decide to do with any cash windfall it will add value for shareholders.

This week has been a good advert for ABDX with volatility in Covid stocks, with ABDX seemingly underpinned by the IPO price with the low free float.

Started to take a position here this week. I believe announcement of the 2 other antigen tests is where ABDX will start to move forward, unless something with ABC-19 comes through in the next week or 2.

Manufacturing capacity will start to shine as where the value is once approvals start to complete for various tests. It remains to be seen if government manufacturing contracts are extended to further manufacturers. I suspect abdx are a month or 2 behind odx in starting to deliver volume of sales, but certainly presents great value any buys in the 80s.

The loaning of the equipment i am sure will be treated like a grant or a forgiven loan. I can't see them wanting it back to set up a production line in Westminster.

But they are investing in some sense of the word in the UK diagnostics industry, but not in the traditional sense where there is an equity interest. It is in the Governments interest that Omega profits and grows to strengthen the diagnostics offering of the country. When the Government talk about investing, it is in infrastructure, building things. The return is the benefit they have to our country, not an equity interest.

Upomega - lol they are not an investor, it is not a RTO.... they are a customer!!! There is no suspension and relisting. It is a contract in the normal course of Omega's business plan, albeit a substantial one.

It's wrong because you divided the £374m contract value by the total number of tests. £374m is just for Omega diagnostics share of the 200m tests, you are underestimating the price. It isnt 200m tests for £374. It is more like £5 per test than £1.97. My guess is GAD will get £560m contract.

Realsit - stupid comment of the day?? How do you think these tests come about? Do you think they grow on trees? Contract for manufacturing/supply of goods. Same thing.

Yes it is very clear which test they are waiting for. It will all become clear very soon and some will have egg on their face, but it wont be me.

The Math is wrong - £374m is just Omega share.

200m tests is the total for ODX and GAD

You are out by a factor of at least 2 you need to double it.

However, i suspect £374m is for 75m tests and GAD may get a larger chunk as it's likely to be their test. In exchange for getting the larger chunk, they give the design to ODX for free. Possible.

Yeah DD because we should judge it by the markets ability to squeeze any life out of it. We know that the sp isn't reacting to news the way we like.

Potential contract value is twice what the mcap is. If people think that is a sell signal they really haven't got a clue

ODX will be making circa 103m tests a year.

If gov take say 50/60%, that is 70% they can sell more profitably elsewhere.

It seems to me the contract is big enough to underpin a chunk of bulk sales but also doesn't prevent them missing out on more profitable sales channels.

DD-please explain in what world is a 9 figure contract not positive?

This is mega for ODX. They have a 9 figure contract!!

It’s not their fault the gov are still ****ing about validating a test. But it doesn’t matter what test they pick.

In the meantime they are stick piling abc-19 tests, they will sell Mologic/visitect test outside Uk gov.

Huge rerate coming here over the coming weeks

Not really had much time or appetite for this BB of late.

TBH not really much to say. I'm sure anyone that knows anything about Omega knows how much upside there is here. Just a few things to add:

It's really frustrating that ODX are not getting the credit and added value they deserve. They have been open and honest about April being the key delivery date for Antigen tests and 2m capacity. We are getting there now, so the time to deliver big news is really running out.

Gov contract - we already have this. I am amazed the lack of detail disclosed in the accounts and lack of impact this had because of it. Everyone has their eyes on Bidstats waiting for disclosure, but it's already signed and we can get a very strong understanding of the agreement from what we know. This is going to be a 100sm £ contract which will be very lucrative for Omega. ABC test and lab test also still have their role to play

Which test - We are yet to see further validation on Mologic test. I am certain it will be there with the best. TT is delayed in announcing, i suspect something going on Mologic's end with the test or waiting for validations rather than technical. Vatic test is a strong contender. Really matters not, Omega will sell everything they make.

People talking about innova contracts - these contracts need replacing and the size of the deals and the short term length of delivery show the opportunity and urgency.

BigJock - i see some attacks against comments made by Bigjock. I know he is one of the more passionate Omega shareholders and has developed a professional/friendly relationship with Colin. I have no doubt that Colin would never disclose inside info, but there is some good information shared by BigJock and should be paid attention to.

Fincapp - i am in no doubt they are doing us no favours. Omega have been in a challenging place financially over the past years. Unfortunately a reliance on the likes of Fincapp in these times is necessary to survival. But these next few months will put an end to that forever. Perhaps fincapp are making sure they get one last payday from Omega? Whatever is going on there, Omega will have more control going forward in their own destiny.

Sad to hear about the passing of founder Andrew Shepherd. 30 years of hard work to get Omega where they are today, I'm sure he would be proud of what Omega have achieved in the last 12 months.

I was vaccinated 5th March shortly after returning a negative ABC-19 test. I have a second test ready to test this Friday 19th. I couldn't imagine taking the vaccine before an antibody test and not wanting to know it is effective afterwards.

This continues to be very undervalued. I am a buyer this week, i wouldn't mind taking one last large chunk at this price. When the only thing you have to complain about is timelines, it presents cheap stock. This really should already be much higher than this.

People are focusing on the Antigen contract news due, but antibody tender announcements also due. Don't rule out the Elisa either, as home collection and lab test with results sent back will satisfy Regulator RE notifiable disease

Hi Okehurst hope you are well.

I’ve looked at recent comms from Avacta and I think they are subtly trying to detract from the idea idea that their test is high on gov priority.

Alex Shepherd Vatic ceo linked in profile is an interesting read.

I still come back to there is nothing any of the parties that you might think are involved can do that Mologic can’t. That’s why they all want to work with Mologic

I certainly think they have been making antibody tests whilst they wait to move forward with antigen.

I suspect TT delay is more to do with Mologic end rather than technical at ODX.

I think the time to deliver tests has been well known, why rush it, get validation right, use the time to carry on with antibody kits